<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01229839</url>
  </required_header>
  <id_info>
    <org_study_id>HCC_S010</org_study_id>
    <nct_id>NCT01229839</nct_id>
  </id_info>
  <brief_title>Chemoembolization With or Without Mixing the Chemotherapy With Lipiodol for Unresectable HCC</brief_title>
  <official_title>Chemoembolization of Unresectable Hepatocellular Carcinoma With or Without Mixing the Chemotherapy With Lipiodol: Effectiveness and Safety. A Prospective and Randomized Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      TACE is considered the standard treatment for unresectable HCC on the basis of the fact that
      there are no alternative to curative procedures.But the optimal combined regimen is still
      unclear. One of the controversy is do the protocol should contain lipiodo and how to
      executer. The investigators hypothesize that TACE without mixing the chemotherapy with
      lipiodol is not unacceptably worse than TACE mixing the chemotherapy with lipiodol.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>3 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">668</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>infusion group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion of anticancer agent followed by Embolization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lipiodol chemotherapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion of mixture of anticancer agent and lipiodol followed by Embolization</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Embolization</intervention_name>
    <description>embolization with lipiodol and polyvinyl alcohol particles (PVA)</description>
    <arm_group_label>infusion group</arm_group_label>
    <arm_group_label>lipiodol chemotherapy group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Infusion of anticancer agent</intervention_name>
    <description>infusion with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg ) desolved in water</description>
    <arm_group_label>infusion group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Infusion of mixture of anticancer agent and lipiodol</intervention_name>
    <description>infusion of mixture of lipiodol and chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg)dissolved in water-soluble contrast medium and distilled water</description>
    <arm_group_label>lipiodol chemotherapy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Eligibility criteria:

        Inclusion Criteria:

          -  Adults patients with a diagnosis of HCC which is not amenable to surgical resection
             ,local ablative therapy and any other cured treatment.

          -  Patients must have at least one tumor lesion that can be accurately measured according
             to EASL criteria. And the lesion has not been previously treated with TACE, surgery,
             radiation therapy, radiofrequency ablation, percutaneous ethanol or acetic acid
             injection, or cryoablation.

          -  No serious concurrent medical illness

          -  Unresectable BCLC stage A-B disease

          -  No cirrhosis or cirrhotic status of Child-Pugh class A

          -  No significant renal impairment (creatinine clearance &lt; 30 mL/minute) or patients on
             dialysis

          -  No current infections requiring antibiotic therapy

          -  Not on anticoagulation or suffering from a known bleeding disorder

          -  No unstable coronary artery disease or recent MI

          -  The following laboratory parameters:

               -  Platelet count ≥ 60,000/µL

               -  Hemoglobin ≥ 8.5 g/dL

               -  Total bilirubin ≤ 1.5 mg/dL Serum albumin ≥ 35 g/L

               -  ASL and AST ≤ 5 x upper limit of normal

               -  Serum creatinine ≤ 1.5 x upper limit of normal

               -  INR ≤ 1.5 or PT/APTT within normal limits

               -  Absolute neutrophil count (ANC) &gt;1,500/mm3

          -  Ability to understand the protocol and to agree to and sign a written informed consent
             document

        Exclusion Criteria:

          -  Known history of HIV

          -  History of organ allograft

          -  Pregnant or breast-feeding patients

          -  Known or suspected allergy to the investigational agents or any agent given in
             association with this trial.

          -  Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy

          -  Evidence of bleeding diathesis.

          -  Patients with clinically significant gastrointestinal bleeding within 30 days prior to
             study entry.

          -  Any other hemorrhage/bleeding event &gt; CTCAE Grade 3 within 4 weeks of first dose of
             study drug

          -  Serious non-healing wound, ulcer, or bone fracture

          -  Known central nervous system tumors including metastatic brain disease

          -  severe Arterioportal Shunts or Arteriavein Shunts
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming Shi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Center, Sun Yat-set University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ming Shi, MD</last_name>
    <phone>86-2087343582</phone>
    <phone_ext>86-2087343582</phone_ext>
    <email>shiming@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rong Ping Guo, MD</last_name>
    <phone>86-2087343117</phone>
    <phone_ext>86-2087343117</phone_ext>
    <email>guorongp@mail.sysu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Center Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Shi, MD</last_name>
      <phone>86-2087343582</phone>
      <phone_ext>86-2087343582</phone_ext>
      <email>shiming@mail.sysu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Rong Ping Guo, MD</last_name>
      <phone>86-2087343117</phone>
      <phone_ext>86-2087343117</phone_ext>
      <email>guorongp@mail.sysu.edu.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Ming Shi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002 May;35(5):1164-71.</citation>
    <PMID>11981766</PMID>
  </reference>
  <reference>
    <citation>Caturelli E, Siena DA, Fusilli S, Villani MR, Schiavone G, Nardella M, Balzano S, Florio F. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of damage to nontumorous liver tissue-long-term prospective study. Radiology. 2000 Apr;215(1):123-8.</citation>
    <PMID>10751477</PMID>
  </reference>
  <reference>
    <citation>Higashi S, Tabata N, Kondo KH, Maeda Y, Shimizu M, Nakashima T, Setoguchi T. Size of lipid microdroplets effects results of hepatic arterial chemotherapy with an anticancer agent in water-in-oil-in-water emulsion to hepatocellular carcinoma. J Pharmacol Exp Ther. 1999 May;289(2):816-9.</citation>
    <PMID>10215657</PMID>
  </reference>
  <reference>
    <citation>Madden MV, Krige JE, Bailey S, Beningfield SJ, Geddes C, Werner ID, Terblanche J. Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma. Gut. 1993 Nov;34(11):1598-600.</citation>
    <PMID>8244149</PMID>
  </reference>
  <reference>
    <citation>Bruix J, Llovet JM, Castells A, Montañá X, Brú C, Ayuso MC, Vilana R, Rodés J. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology. 1998 Jun;27(6):1578-83.</citation>
    <PMID>9620330</PMID>
  </reference>
  <reference>
    <citation>Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000 Feb 2;92(3):205-16.</citation>
    <PMID>10655437</PMID>
  </reference>
  <reference>
    <citation>Ono Y, Yoshimasu T, Ashikaga R, Inoue M, Shindou H, Fuji K, Araki Y, Nishimura Y. Long-term results of lipiodol-transcatheter arterial embolization with cisplatin or doxorubicin for unresectable hepatocellular carcinoma. Am J Clin Oncol. 2000 Dec;23(6):564-8.</citation>
    <PMID>11202797</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2010</study_first_submitted>
  <study_first_submitted_qc>October 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2010</study_first_posted>
  <last_update_submitted>December 6, 2016</last_update_submitted>
  <last_update_submitted_qc>December 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Shi Ming</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Carcinoma,Hepatocellular</keyword>
  <keyword>Liver Neoplasms</keyword>
  <keyword>Therapeutic</keyword>
  <keyword>Chemoembolization,</keyword>
  <keyword>TACE</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>Iodized Oil/administration &amp; dosage</keyword>
  <keyword>polyvinyl alcohol</keyword>
  <keyword>Humans</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethiodized Oil</mesh_term>
    <mesh_term>Antineoplastic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

